VYNE Therapeutics (VYNE) Enterprise Value (2016 - 2026)
VYNE Therapeutics (VYNE) posted Enterprise Value of -$24.9 million for Q1 2026, up 14.07% on a QoQ basis from -$29.0 million in Q4 2025, and up 50.41% year-over-year from -$16.6 million in Q1 2025.
VYNE Therapeutics (VYNE) Enterprise Value (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Enterprise Value history runs 11 years deep, the most recent figure standing at -$24.9 million for Q1 2026.
- Quarterly Enterprise Value rose 50.41% year-over-year to -$24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.9 million (up 50.41% YoY) and the FY2025 annual result came in at -$29.0 million, up 52.84% from the prior year.
- Enterprise Value was -$24.9 million for Q1 2026 at VYNE Therapeutics, up from -$29.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at $144000.0 in Q4 2022 and bottomed at -$86.0 million in Q1 2024.
- A 5-year average of -$40.7 million and a median of -$41.2 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 123.8% — and 2024, when it sank 129872.22%.
- VYNE Therapeutics' Enterprise Value stood at $144000.0 in 2022, then sank by 43632.64% to -$62.7 million in 2023, then advanced by 1.87% to -$61.5 million in 2024, then jumped by 52.84% to -$29.0 million in 2025, then gained by 14.07% to -$24.9 million in 2026.
- Business Quant data shows VYNE's Enterprise Value at -$24.9 million in Q1 2026, -$29.0 million in Q4 2025, and -$39.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -24.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.93 Mn |
| Dec 31, 2025 | -29.01 Mn |
| Jun 30, 2025 | -39.65 Mn |
| Mar 31, 2025 | -50.27 Mn |
| Dec 31, 2024 | -61.52 Mn |
| Sep 30, 2024 | -70.19 Mn |
| Jun 30, 2024 | -78.10 Mn |
| Mar 31, 2024 | -85.95 Mn |
| Dec 31, 2023 | -62.69 Mn |
| Sep 30, 2023 | -54,000.00 |
| Jun 30, 2023 | -20.63 Mn |
| Mar 31, 2023 | -67,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Sep 30, 2022 | -35.51 Mn |
| Jun 30, 2022 | -42.81 Mn |
| Mar 31, 2022 | -50.50 Mn |
| Dec 31, 2021 | -605,000.00 |
| Sep 30, 2021 | -52.31 Mn |
| Jun 30, 2021 | -605,000.00 |
| Mar 31, 2021 | -119.54 Mn |